Stockreport

Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 [Yahoo! Finance]

Candel Therapeutics, Inc.  (CADL) 
PDF Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec [Read more]